(4alpha,7beta)-7-Hydroxy-4-methyl-3,11-dioxoergosta-8,14,24(28)-trien-26-oic acid | 172549-40-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (4alpha,7beta)-7-Hydroxy-4-methyl-3,11-dioxoergosta-8,14,24(28)-trien-26-oic acid
• 英文别名: (6R)-6-[(4S,7S,10S,13R,17R)-7-hydroxy-4,10,13-trimethyl-3,11-dioxo-2,4,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-3-methylideneheptanoic acid
• CAS: 172549-40-5
• 化学式: C₂₉H₄₀O₅
• 分子量: 468.6
• InChiKey: ZPSJWLSADLCKBZ-GIMPTUAXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• PHARMACEUTICAL COMPOSITION FOR TREATING CANCER IN AN INDIVIDUAL SUBJECT SUFFERING CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170042912A1

  公开（公告）日：2017-02-16

  A pharmaceutical composition for treating cancer in an individual, comprising at least a pharmaceutically effective amount of a novel target HCC reversal signal substance, and a pharmaceutically acceptable ingredient comprising a vehicle, a carrier, a diluent or an excipient; in which the ratio among each component of the pharmaceutical composition may be adjustable depending on the type of cancer; wherein the novel target HCC reversal signal substance comprises at least one selected from the group consisting of antroquinonol (AQL), antrocinnamonin A (ACA), antroquinonol B (AQB), antroquinonol D (AQD), dehydroeburicoic acid (DEA), dehydrosulphurenic acid (DSA), zhankuic acid A (ZAA), zhankuic acid C (ZAC), antcin K (ANK), antcin C (ANC), and a mixture thereof.
• PHARMACEUTICAL COMPOSITION FOR TREATING BREAST CANCER
  申请人：MA SHEN KAI RUEi CO., LTD.

  公开号：US20170189416A1

  公开（公告）日：2017-07-06

  The present invention provides a pharmaceutical composition for treating breast cancer in a subject in need thereof, which comprises a first agent comprising at least a dehydroeburicoic acid (DeEA); and a second agent comprising at least an Antroquinonol B (AnQB); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of Antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of breast cancer or to prevent or to reduce the risk of a breast cancer metastasizing, compared to administration of the first agent or the second agent alone.
• PHARMACEUTICAL COMPOSITION FOR TREATING PROSTATE CANCER
  申请人：MA SHEN KAI RUEI CO., LTD.

  公开号：US20170189419A1

  公开（公告）日：2017-07-06

  The present invention provides a pharmaceutical composition for treating prostate cancer in a subject in need thereof, which comprises a first agent comprising at least a Anctin K (AnK); and a second agent comprising at least an Antroquinonol B (AnQB); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of Antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of prostate cancer or to prevent or to reduce the risk of a prostate cancer metastasizing, compared to administration of the first agent or the second agent alone.